Arkansas Cardiology Symposium

Registration Form







    If there are any issues regarding filling out the form please email Amy at awyles@arcard.org

    7:00 a.m. Registration, Continental Breakfast, and Exhibits


    7:50 a.m.     Welcome and Opening Remarks, Invocation

      Jay Geoghagan, MD, FACC
      David Jones, MD, FACC
      Steve Greer, MD, FACC, FACP

    8:00 a.m. Dysautonomia

    Steve Greer, MD, FACC


    8:30 a.m.     Screening Consequences: Coronary and Aortic Calcification

    Christen Johnson, MD

    9:00 a.m. Interpretation of Non-Invasive Testing

      Kirby Von Edwin, MD, FACC

    9:30 a.m. Morning Break and Exhibits

    9:45 a.m. Patient Experience: TAVR (Video)

      Aaron Strobel, MD

    10:15 a.m. Lipid Management: Statins and Alternatives

      Charles Caldwell, MD, FACC

    10:45 a.m. Diabetes Drugs for Non-Diabetics with Cardiac Risk/Disease (SGLT2i/GLP-1)

      Ramey Marshell, MD

    11:15 a.m. Peripheral Artery Disease: Basics for the PCP

      Hani Turkmani, MD

    11:45 a.m. Lunch and Exhibits

    12:45 p.m. EKG Rapid Fire

      Jay Geoghagan, MD, FACC

    1:15 p.m. A Review of the Clinic Management of Acute/Subacute TIA/Stroke

      Joe Hackler, DO, FACC

    1:45 p.m. Vitamins and Supplements: What is evidence in Heart Disease

      Tom Conley, MD, FACC, FSCAI

    2:15 p.m. Afternoon Break and Exhibits

    2:30 p.m. Coronary Artery Disease

      Faheem Beg, MD, FACC

    3:00 p.m. Left Atrial Appendage Devices

      Blake Norris, MD, FACC

    3:30 p.m. Adjourn

    Objectives

    • Review ACC/AHA guidelines related to the treatment of poorly controlled hypertension.
    • Review options for hypertension management.
    • Discuss types of Aortopathy.
    • Review known causes of Aortopathy.
    • Discuss the appropriate duration of dual antiplatelet therapy after coronary stenting.
    • Review the data for short- and long-term dual anti-platelet therapy.
    • Discuss sports recommendations in post-COVID patients.
    • Know the rationale and suggested use of the AHA/ACC Eligibility and Disqualification Recommendations for Competitive Athletes.
    • Review the current technological advances in the interventional management ofstructural heart diseases, including minimally invasive heart valve interventionson aortic, mitral and tricuspid disease.
    • Discuss improvements to safety, quality and patient satisfaction surroundingnon-surgical structural procedures.
    • Discuss risk factors for Women with known coronary artery disease.
    • Evaluate treatment options for Women with known coronary artery disease.
    • Explain how managing health behaviors and risk factors are an important aspectof lowering the risk of cardiovascular disease.
    • Discuss exercise strategies for patients with known cardiac disease.
    • Review clinical treatment strategies to address patients with Heart Failure withReduced Ejection Fraction (HFrEF).
    • Assess the implications of new treatments for HFrEF.
    • Review clinical treatment strategies to address patients with Heart Failure withpreserved Ejection Fraction (HFpEF).
    • Assess medications used to treat HFpEF.
    • Review normal and abnormal ECG findings.
    • Determine appropriate treatment options for specific arrhythmias.
    • Review clinical literature relating to novel anticoagulant medications.
    • Discuss the complications of atrial fibrillation and the reasoning behind theprescribing of an anticoagulant.
    • Review Dietary trends and discuss the role they play in overall CardiovascularHealth.